The new production plant and corporate headquarters will be developed over a built-up area covering about 17,000 sq. meters and will be expected to require an investment of about 140 million Euros.
Piombino Dese (Padua, Italy), 30 August 2018 - Stevanato Group, an international leader specializing in systems, processes, and services for the pharmaceutical industry, will be extending its main premises in Piombino Dese (Padua) and building a new production plant and corporate headquarters. Set to cover a built-up area of about 17,000 square meters, the site will house about 300 employees, office staff, and factory workers. The total expected investment will amount to about 140 million Euros, to be staggered over the next five years.
The new premises are part of a long-term development process envisioned by the Group which has 14 production sites in 9 different countries all over the world and is set on offering its customers, in the pharmaceutical industry, a comprehensive service by delivering integrated and complete systems for administering medicines. The design of the new site will cater to an increased manufacturing capacity of syringes and the production of advanced devices for administering medicines, using state-of-the-art robotics and ultramodern information infrastructures. The idea is to develop a true smart “Factory 4.0” of the future.
The extension project is divided into three stages: the first one (which is due to be completed at the end of the year) will involve building production premises and a warehouse on a built-up area of about 14,000 sq.m., whilst the second phase (which should be completed by the first half of 2020) relates to the creation of the new head offices which will boast a layout and general set-up with a provision of services able to create an ideal working environment for the employees. Then, after 2020, an increase in manufacturing capacity is expected due to the estimated growth in demand for devices administering medicines.
“Extending our head offices is another milestone in our game plan for growth. We are especially proud that we were able to do it here at Piombino Dese where we have our roots, and which has offered us ideal conditions for development,” states Franco Stevanato, CEO of Stevanato Group. “The production premises have been designed to house best-in-class technologies developed within our Group for administering parenteral drugs. This move will enable us to step up our ability to offer value-added systems and strategically important productions for the growth and future development of the Company.”
The investment required to build these new production facilities will increase the investments already envisioned to take place by 2020 to boost the manufacturing capacity for sterile products, EZ-fill, of the Piombino Dese site amounting to 20 million Euros.
About Stevanato Group:
Founded in 1949, the Stevanato Group is the world’s largest privately-owned designer and producer of glass parenteral packaging for the pharmaceutical industry. It comprises two operational divisions dedicated to serving the pharmaceutical industry. The Pharmaceutical Systems division comprises Ompi, specializing in glass primary packaging, and Balda, focused on specialty plastics and delivery devices. The Engineering Systems division comprises Spami, Optrel, InnoScan and SVM, specializing in glass processing, inspection systems, assembly and packaging solutions. These two divisions enjoy a close, mutually supportive relationship, which ensures that Stevanato Group has complete control over the entire production process. The Group also benefits from the SG Lab activity that provides technical and analytical services on the potential interaction between drug and container.
For more information please visit www.stevanatogroup.com